1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Urethral Diseases: new trials by email Literature Review of Urethral Diseases trials Research Report on Urethral Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer enfortumab vedotin (EV), pembrolizumab, cisplatin - Carcinoma, Transitional Cell, Urinary Bladder Neoplasms | Phase 1 / Phase 2 | Terminated | Astellas Pharma Global Development, Inc. | 348 | 2017-10-11 | 2026-03-24 |
Carcinoma, Transitional Cell (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1) · Urinary Bladder Neoplasms (1) · Urologic Neoplasms (1)
Carcinoma (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Ureteral Diseases (1) · Urinary Bladder Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Urologic Diseases (1)
Carboplatin (1) · Cisplatin (1) · Gemcitabine (1) · enfortumab vedotin (1) · pembrolizumab (1)
Astellas Pharma Global Development, Inc. (1)
Canada (1) · France (1) · Italy (1) · Puerto Rico (1) · Spain (1) · United States (1)
Changting Meng, MD (1) · Jason Lukas, MD, PhD (1)